CD4 and neoplasm: Highly attenuated, live Lm strains, engineered to express tumor associated antigens (TAA) fused to a truncated LLO, can therefore induce potent anti-tumor CD8+ and CD4+ T cell responses that break peripheral tolerance and lead to regression of target-antigen+tumors [35–37].